Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer

医学 围手术期 肺癌 化疗 外科 阶段(地层学) 淋巴结 安慰剂 随机对照试验 癌症 临床试验 内科学 纵隔淋巴结 癌 肿瘤科 全肺切除术 腺癌
作者
Wentao Fang,Yiyang Wang,Wenxiang Wang,Lin Wu,Longhua Sun,Peng Zhang,Shun Lu,Neotorch Investigators,Yan Zheng,Qixun Chen,Lijie Tan,Lin Yang,Jiandong Mei,Xiaohong Sun,Shidong Xu,Jinlu Shan,Nong Yang,Dongliang Yu,Yuping Chen,Guohua Yu
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:161 (9): 881-881 被引量:3
标识
DOI:10.1001/jamasurg.2026.2711
摘要

Importance: Perioperative immunotherapy has improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). The influence of immune checkpoint inhibitor in combination with chemotherapy on surgical outcomes remains to be explored. Objective: To evaluate perioperative toripalimab in combination with chemotherapy on surgical outcomes. Design, Setting, and Participants: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (Neotorch study) enrolled patients with resectable stage III NSCLC and took place at 50 centers in China. Patients who had histologically confirmed resectable stage IIIA or IIIB NSCLC were eligible. These data were analyzed from July 2024 to March 2026. Interventions: Patients were randomized (1:1) to receive toripalimab (240 mg) plus platinum-based chemotherapy or placebo plus platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by maintenance with toripalimab or placebo alone for 13 cycles. Main Outcomes and Measures: Surgical outcomes, including perioperative complications, tumor downstaging, and lymph node downstaging, and their association with event-free survival (EFS), were studied in this post hoc analysis. Results: Among 404 patients enrolled, 314 patients (median [SD] age 60 [6.82] years; 90% of patients were male and 10% were female) underwent surgery (166 in toripalimab group and 148 in placebo group). Percentage of patients canceling surgery (17.8% vs 26.7%; P = .03) was significantly lower in the toripalimab group. Proportions of minimally invasive surgery, R0 resection, and lobectomy were slightly higher in the toripalimab group. Surgical complications were similar between the 2 groups. Rates of postsurgery tumor (80.7% vs 50.7%; P < .001) and lymph node downstaging (67.5% vs 48.6%; P = .001) were both significantly higher with toripalimab than placebo. With a median follow-up of 18.3 months, a better EFS was noticed in the toripalimab group. Tumor and lymph node downstaging in the toripalimab group were both associated with better EFS than nondownstaging (median EFS, not estimable [NE] vs 17.5 months; P = .004 and NE vs 19.2 months; P = .001, respectively), and were also associated with even better EFS than tumor and lymph node downstaging in the placebo group (median EFS, NE vs 22.0 months; P = .002 and NE vs NE; P = .009, respectively). Conclusions and Relevance: In this study, perioperative toripalimab plus chemotherapy showed comparable perioperative outcomes, as with chemotherapy alone without new safety signals, and could help improve survival through effective tumor downstaging in patients with resectable stage III NSCLC. Trial Registration: ClinicalTrials. gov Identifier: NCT04158440.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
自由土豆完成签到,获得积分10
刚刚
1秒前
wyc发布了新的文献求助10
2秒前
3秒前
FashionBoy的应助被开心快乐大王采纳,获得10
3秒前
3秒前
璐璇完成签到 ,获得积分10
5秒前
guofuyan完成签到 ,获得积分10
5秒前
5秒前
6秒前
molihuakai的应助被苗条梨愁采纳,获得10
6秒前
乐乐的应助被苗条梨愁采纳,获得10
6秒前
小蘑菇的应助被苗条梨愁采纳,获得10
6秒前
完美世界的应助被木染采纳,获得10
7秒前
汉堡包的应助被可恶地采纳,获得10
8秒前
8秒前
路人发布了新的文献求助10
8秒前
Jasper的应助被ZBH采纳,获得10
8秒前
CipherSage的应助被WTTPAXL采纳,获得10
8秒前
之予无为完成签到,获得积分10
9秒前
9秒前
水煮电吹风的应助被胡萝卜卜采纳,获得10
9秒前
我拿迪迦咋啦完成签到,获得积分10
9秒前
9秒前
小气杨桃完成签到,获得积分10
10秒前
Olivia完成签到,获得积分10
10秒前
清秀千兰发布了新的文献求助10
11秒前
Orange的应助被ZZKKZZ采纳,获得10
11秒前
11秒前
snail完成签到,获得积分10
11秒前
古娜拉完成签到,获得积分10
12秒前
之予无为发布了新的文献求助10
12秒前
大碗完成签到,获得积分10
12秒前
13秒前
Lucas的应助被路人采纳,获得10
16秒前
16秒前
烟花的应助被Dafu采纳,获得30
16秒前
17秒前
molihuakai的应助被尔尔采纳,获得10
18秒前
无敌完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541